Nektar Therapeutics (NKTR) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -297.1%, revenue growth -9.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $55.23M |
| Revenue (TTM) | $0.1B |
| Net Margin | -297.1% |
| Operating Margin (TTM) | -257.8% |
| Revenue Growth (YoY) | -9.3% |
| EPS Growth (YoY) | -58.3% |
| FCF Growth (YoY) | 65.7% |
| Price / Book | 2.80 |
| Price / Sales | 46.28 |
| FCF Yield | -9.3% |
| Altman Z-Score | -12.63 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
NKTR overview · NKTR earnings · NKTR KPIs · NKTR documents · NKTR ownership · NKTR peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.